Press release
Anemia Treatment Market Size in 7MM is expected to grow at a decent CAGR by 2032, estimates DelveInsight
DelveInsight's "Anemia Market Insights, Epidemiology, and Market Forecast- 2032" report delivers an in-depth understanding of the Anemia, historical and forecasted epidemiology as well as the Anemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.Unlock key insights into the Anemia Market! Download DelveInsight's comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ Anemia Therapeutics Market Outlook [https://www.delveinsight.com/sample-request/anemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Anemia Market Report
* In April 2025, GlaxoSmithKline announced a study will enroll participants with anemia associated withCKD, in 2 distinct sub-populations differing only by their CKD stage and dialysis requirement (ND: CKD stage 3 to 5 not yet receiving dialysis and D: CKD stage 5d undergoing peritoneal dialysis [PD] or hemodialysis [HD]).
* In April 2025, Bristol-Myers Squibb conducted a phase 4 study to Evaluate Safety and Effectiveness of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) With Ring Sideroblasts Who Require Red Blood Cell Transfusions in Participants Who Have Had Unsatisfactory Response to or Are Ineligible to Erythropoietin Based Therapy and in Participants With Transfusion Dependent Anemia Due to Beta-Thalassemia.
* In April 2025, American Regent Inc . conducted a study is to evaluate the safety and tolerability of VIT-45 in the treatment of Iron Deficiency Anemia.
* According to World Health Organization (2011), it is estimated that roughly 43% of children, 38% of pregnant women, and 29% of non pregnant women and 29% of all women of reproductive age had anaemia.
* In a study by Sun and Wiever (2021), the US population was studied between 1999 and 2018, it was seen that dietary iron intake decreased by 6.6% and 9.5% for male and female adults, respectively. Increases of prevalence of estimated anemia in the United States ranged from 10.5% to 106% depending on age and gender.
* According to Office on Women's Health (OWH), Iron-deficiency anemia affects more women than men and is more common during pregnancy.
* The increase in Anemia Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
* As per DelveInsight analysis, the Anemia Market is anticipated to witness growth at a considerable CAGR.
* The leading Anemia Companies such as GSK, MegaPro Biomedical, Agios Pharmaceuticals, Nemysis and others.
* Promising Anemia Pipeline Therapies such as IHAT-02/IDAX, AG-946, MPB-1514/ IOP Injection , and others.
Stay ahead in the competitive landscape of the Anemia Market. Access DelveInsight's in-depth market analysis and strategic insights today! Click here for more @ Anemia Treatment Market Size [https://www.delveinsight.com/sample-request/anemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Anemia Epidemiology Segmentation in the 7MM
The epidemiology section of Anemia offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.
Download the report to understand which factors are driving Anemia epidemiology trends @ Anemia Prevalence [https://www.delveinsight.com/sample-request/anemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Emerging Anemia Drugs
* Akebia Therapeutics: Vadadustat
Vadadustat (Akebia Therapeutics) is an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor designed to mimic the physiologic effect of altitude on oxygen availability. At higher altitudes, the body responds to lower oxygen availability with stabilization of hypoxia-inducible factor, which can lead to increased red blood cell production and improved oxygen delivery to tissues. Vadadustat recently completed its global Phase III clinical development program for the treatment of anemia due to CKD. It is an investigational drug that has not been approved by the U.S. Food and Drug Administration (FDA) or any regulatory authority for use outside of Japan.
* GlaxoSmithKline: Daprodustat /GSK1278863
Daprodustat /GSK1278863 (GlaxoSmithKline) is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), for the treatment of patients with anaemia due to chronic kidney disease (CKD). Daprodustat is currently not approved as a treatment for anaemia due to CKD or any other indication anywhere else in the world other than in Japan. Presently it is being evaluated in Phase III study for treatment of Anemia.
* Nemysis: IHAT-02/ IDAX
IHAT-02/ IDAX (Nemysis), is novel oral iron formulation, the first natural ferritin mimic, where a tartrate salt is used to "dope" the ferrihydrite nanocore of ferritin, in an adipate buffer. IHAT (Iron Hydroxide Adipate Tartrate) is well absorbed and preserves the gut microbiome. Absorption studies and early nutritional trials in human have shown that IHAT is absorbed efficiently and corrects markers of iron deficiency, without the burden of gastrointestinal side effects. Currently the drug is being evaluated in a Phase II clinical trial for the treatment of Iron deficiency/ Anemia. The company was the first to file a nano iron [IHAT nano-ferric (III)] for approval by the European Food Safety Authority.
* MegaPro Biomedical: MPB-1514/ IOP Injection
MPB-1514/ IOP Injection (MegaPro Biomedical), is the non- sugar iron injection being developed for the treatment of Iron deficiency anemia. It is highly secure as coated with PEG with good macrophage phagocytic results, high doses can be injected, which can effectively increase the number of red blood cells without frequent injections, providing greater convenience and compliance with doctor's orders for patients. The drug is currently being evaluated in a Phase II clinical study with iron deficient anemia patients.
Anemia Drugs Market
The Anemia Drugs Market is expected to witness substantial growth in the coming years as more targeted therapies receive regulatory approval and enter clinical practice. Additionally, ongoing research efforts aimed at better understanding the molecular mechanisms underlying Anemia signaling in Anemia are likely to uncover new therapeutic targets and further expand treatment options for patients.
Anemia Treatment Market Landscape
The Anemia treatment market landscape has witnessed significant advancements over the past years, with targeted therapies playing a crucial role in improving outcomes for patients. Among these targeted therapies, the emergence of Anemia has garnered attention in the medical community, presenting both challenges and opportunities in treatment strategies.
To learn more about Anemia treatment guidelines, visit @ Anemia Market Drivers and Barriers [https://www.delveinsight.com/sample-request/anemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Anemia Companies
GSK, MegaPro Biomedical, Agios Pharmaceuticals, Nemysis and others.
Anemia Market Outlook
The report's outlook on the Anemia market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Anemia therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Anemia drug and late-stage pipeline therapy.
Anemia Drugs Uptake
The drug chapter of the Anemia report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Anemia.
Explore the dynamics of the Anemia Market with DelveInsight. From market size to emerging drugs-find it all in our latest report. Read now! @ Anemia Ongoing Clinical Trials Analysis [https://www.delveinsight.com/sample-request/anemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Anemia Market Report
- Coverage- 7MM
- Study Period- 2019-2032
- Anemia Companies- GSK, MegaPro Biomedical, Agios Pharmaceuticals, Nemysis and others.
- Anemia Pipeline Therapies- IHAT-02/IDAX, AG-946, MPB-1514/ IOP Injection , and others.
- Anemia Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Anemia Unmet Needs, KOL's views, Analyst's views, Anemia Market Access and Reimbursement
Table of Contents
1. Key Insights
2. Executive Summary of Anemia
3. Competitive Intelligence Analysis for Anemia
4. Anemia: Market Overview at a Glance
5. Anemia: Disease Background and Overview
6. Anemia Patient Journey
7. Anemia Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Anemia Unmet Needs
10. Key Endpoints of Anemia Treatment
11. Anemia Marketed Products
12. Anemia Emerging Therapies
13. Anemia: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Anemia Market Outlook
16. Access and Reimbursement Overview of Anemia
17. Anemia KOL Views
18. Anemia Market Drivers
19. Anemia Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=anemia-treatment-market-size-in-7mm-is-expected-to-grow-at-a-decent-cagr-by-2032-estimates-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/anemia-market
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Anemia Treatment Market Size in 7MM is expected to grow at a decent CAGR by 2032, estimates DelveInsight here
News-ID: 3993473 • Views: …
More Releases from ABNewswire

Total Joy Homecare Responds to Surging Demand for Senior Health Care Services in …
Total Joy Homecare expands services to meet growing Houston demand for in-home senior care, offering non-medical support that helps families maintain independence and dignity at home.
Houston's rapidly aging demographic has prompted local care provider Total Joy Homecare to expand its comprehensive support services, addressing the critical need for quality senior health care services [https://maps.app.goo.gl/hUcW1N7qWy5EdHJs5] throughout the Greater Houston area. The company's response comes as families increasingly seek reliable alternatives to…

Texas Company Introduces On-Site Carrier Repair Services to Reduce Fleet Downtim …
Texas Reefer Solutions introduces mobile carrier repair services in Dallas, revolutionizing how transportation fleets handle refrigeration breakdowns by providing on-site professional repairs, eliminating route deviations, and reducing cargo-threatening delays.
The transportation industry faces a significant challenge when refrigerated trucks require repairs, often forcing drivers to deviate from critical routes and schedules. Texas Reefer Solutions has emerged as a game-changing solution, introducing mobile carrier repair services [https://maps.app.goo.gl/P6nfg5WF7sckR7aZ8] that bring professional technicians directly…

Family Therapy in Birmingham: How the Right Therapist Can Transform Relationship …
Family therapy in Birmingham helps families improve communication, resolve conflict, and build stronger bonds. With the support of a qualified therapist near you, therapy creates a safe space to share, heal, and reconnect. Whether you're searching for therapy near me or counselling for your family, Phinity Therapy offers guidance for lasting change.
Families are the foundation of our lives. They provide love, support, and connection, but they can also be the…

Multiple Sclerosis Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Tri …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Multiple Sclerosis pipeline constitutes 75+ key companies continuously working towards developing 80+ Multiple Sclerosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Multiple Sclerosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed…
More Releases for Anemia
Rising Cancer And Anemia Cases Propel Growth In Chemotherapy-Induced Anemia Mark …
The Chemotherapy-Induced Anemia Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Chemotherapy-Induced Anemia Market Size During the Forecast Period?
The Chemotherapy-Induced Anemia Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This…
Iron Deficiency Anemia Market Analysis 2034 | Iron Deficiency Anemia Therapies, …
As per DelveInsight, the Iron Deficiency Anemia Market is anticipated to grow immensely in the coming years owing to the launch of upcoming therapies and the increase in the incident population of Iron Deficiency Anemia in the 7MM.
DelveInsight's "Iron Deficiency Anemia Market Insights, Epidemiology, and Market Forecast 2034 [https://www.delveinsight.com/report-store/iron-deficiency-anemia-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Iron Deficiency Anemia market size,…
Aplastic Anemia Treatment Market - Shaping the Future of Aplastic Anemia Health: …
Newark, New Castle, USA: The "Aplastic Anemia Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Aplastic Anemia Treatment Market: https://www.growthplusreports.com/report/aplastic-anemia-treatment-market/8435
This latest report researches the industry structure,…
Anemia Drugs Market 2018 Grow at CAGR of 8.4% to Reach USD 34.7 Billion | By Uni …
Market Research Future Published a Prime research Report on “Global Anemia Drugs Market Research Report - Forecast to 2022” – Market Analysis, Scope, Stake, Progress, Trends and Forecast to 2022
Global Anemia Drugs Market - Segments
Global anemia drugs market has been segmented on the basis of anemia type which comprises iron deficiency anemia, sickle cell anemia, aplastic anemia, hemolytic anemia pernicious anemia and others. On the basis of route of administration;…
Anemia in Chronic Kidney Disease (Renal Anemia) - Industry Analysis, Trends, and …
Market Research Hub (MRH) has recently announced the addition of a fresh report, titled “Anemia in Chronic Kidney Disease Pipeline Review, H1 2017” to its report offerings. The report provides an overview of the Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) pipeline landscape.
Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1196648
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline Review, H1 2017,…
Global Anemia in Chronic Kidney Disease (Renal Anemia) Clinical Trials Market Re …
Market Research Hub's clinical trial report, Global Anemia in Chronic Kidney Disease (Renal Anemia) Clinical Trials Review, H1, 2017, provides an overview of Anemia in Chronic Kidney Disease (Renal Anemia) clinical trials scenario. This report provides top line data relating to the clinical trials on Anemia in Chronic Kidney Disease (Renal Anemia). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe.
Request…